A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio’s Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in a wide array of discovery applications.
The collaboration integrates Telesis Bio’s Gibson SOLA Enzymatic Synthesis technology with the new Biomek Echo One System from Beckman Coulter Life Sciences. It also delivers an open solution to the market, allowing the incorporation of constructs from other providers compatible with Gibson SOLA, further expanding the technology’s flexibility to synthesize unique or challenging biology.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.